BioNTech's Sean Marett Explains Genentech Deal Rationale
Executive Summary
Chief operating officer of BioNTech Sean Marett talks to Mike Ward, global director of content for Informa Pharma Intelligence, about the German firm's recent co-development deal with Roche company Genentech.
You may also be interested in...
Genentech's Associate Oncology Director Talks Cancer Vaccine Challenges
Peter Fong, associate director of oncology business development at Genentech – a division of Roche – talks to Scrip about the company's latest deal with BioNTech in oncology vaccines and why Genentech is predicting success this time around for more cancer vaccine products, especially when used in combination with newer immunotherapy options.
Genentech, BioNTech Pact Aims To Make Targeted Cancer Vaccines
Genentech will tap expertise of privately-held BioNTech in a collaboration aimed at developing individually tailored vaccines for use against a broad range of cancers, which the duo says offers “a new treatment paradigm” for oncology.
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.